Trial
NCT01005875
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Alabama at Birmingham
Collaborators
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Condition
Hepatocellular Carcinoma
Intervention
Sorafenib
Why stopped
Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-10